SEC For	rm 4 FORM	4	UNITEI	O STA	TES S	ECUR	RITIE	ES AND	E	ХСНА	NGE C	омм	ISSION					
			Washington, D.C. 20549											OMB A			VAL	
Sectio obligation	this box if no long the second se	STA		d pursuar	T OF CHANGES IN BENEFICIAL OWNI							SHIP	Estim	OMB Number: 32 Estimated average burden hours per response:		3235-0287 en 0.5		
1. Name and Address of Reporting Person [*] <u>Raffin Thomas A.</u>						2. Issuer Name and Ticker or Trading Symbol Akoya Biosciences, Inc. [AKYA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)	, , , , , ,				3. Date of Earliest Transaction (Month/Day/Year) 06/01/2023								Officer below)	(give title		Other (below)	specify	
100 CAMPUS DRIVE, 6TH FLOOR					4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable e)				
(Street) MARLBOROUGH MA 01762													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Noi	ו-Deriv	ative S	ecuritie	s Ac	quired, D	Disp	osed o	of, or Bei	neficial	ly Owned	d				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Dat					Execution Date,		Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securities Beneficially Owned Fol		Form (D) o	vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
		I						uired, Dis , options					/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 34. Deemed Execution Date, if any (Month/Day/Year)		Date,	4. Transactio Code (Insti 8)	ansaction of E ode (Instr. Derivative (6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	ve Owners es Form: ially Direct (I or Indire ng (I) (Instr d tion(s)		Beneficial Ownershi (Instr. 4)		
1	1		1		1	1	1				I	Amount		1			1	

(D) Date Exercisable

1. Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.

(1)

Expiration Date

06/01/2033

Title

Fact

Common Stock

** Signature of Reporting Person Date

or Number

of Shares

56,322

<u>/s/ Thomas A. Raffin, by Brian</u> <u>McKelligon, as Attorney-in-</u>

\$0.00

56,322

06/05/2023

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/01/2023

Stock Option (Right to Buy)

\$5.7

Explanation of Responses:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Code

A

V (A)

56,322

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.